[{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cebranopadol","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tris Pharma Inc","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Tris Pharma Inc \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cebranopadol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tris Pharma Inc \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cebranopadol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.

                          Brand Name : TRN-228

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 21, 2024

                          Lead Product(s) : Cebranopadol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...

                          Brand Name : TRN-228

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 28, 2023

                          Lead Product(s) : Cebranopadol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : National Institute on Drug Abuse

                          Deal Size : $16.6 million

                          Deal Type : Funding

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.

                          Brand Name : TRN-228

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 13, 2022

                          Lead Product(s) : Cebranopadol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.

                          Brand Name : PRK-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 29, 2021

                          Lead Product(s) : Cebranopadol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Tris Pharma Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank